Trade ANVS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Annovis Bio, Inc. (ANVS) is trading at US$1.77, down 2.49% today as of Aug 28, 11:24 EDT. The company has a market capitalisation of US$77.54M. Over the past 52 weeks, ANVS has traded between US$1.54 and US$5.50. On Syfe you can trade ANVS with $0 commission and add it to your watchlist.
| Previous close | US$1.81 |
|---|---|
| Market cap | US$77.54M |
| 52-week range | US$1.54 – US$5.50 |
| Volume | 292.17K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
Year: 2020
--Roth Capital Initiates Annovis Bio at Buy With $8 Price Target
Jul 8, 12:03 PM · MT Newswires
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease
Jul 7, 11:18 AM · MT Newswires
Annovis Bio Launches Proposed Stock, Warrant Offering; Shares Fall
May 19, 9:02 PM · MT Newswires
Annovis Bio, Inc. (ANVS) stock is trading at US$1.77, -2.49% from the previous close of US$1.81.
The market cap for Annovis Bio, Inc. (ANVS) stock is approximately US$77.54M.
The 52-week high for Annovis Bio, Inc. (ANVS) stock is US$5.50.
The 52-week low for Annovis Bio, Inc. (ANVS) stock is US$1.54.
Annovis Bio, Inc. (ANVS) does not currently pay a dividend.
Stay on top of ANVS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
